Fulgent Genetics shareholders approve 2026 equity plan authorizing 2M new shares

Fulgent Genetics, Inc.

2026 Equity Incentive Plan replaces prior 2016 plan; authorizes 2,000,000 new shares plus up to 1,500,000 from forfeited awards.
All four director nominees elected: Ming Hsieh, Linda Dong, Michael Nohaile, Regina Groves (each to serve until 2027 annual meeting).
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026 approved (24.5M for, 87K against).
Non-binding advisory vote on named executive officer compensation passed (19.8M for, 2.4M against, 45K abstain).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Fulgent Genetics, Inc. shareholders approved Approval of the Company's 2026 Equity Incentive Plan. at the 2026-05-14 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-05-14

Exact text from the filing

Proposal 4 Approval of the Company's 2026 Equity Incentive Plan. Votes For Votes Against Votes Abstained Broker Non-Vote 18,693,758 3,513,983 48,202 2,323,053

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Fulgent Genetics, Inc. shareholders approved Election of the following nominees as directors of the Company, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. at the 2026-05-14 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-14

Exact text from the filing

Proposal 1 Election of the following nominees as directors of the Company, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. Votes For Votes Withheld Broker Non-Vote Ming Hsieh 21,979,668 276,275 2,323,053 Linda Dong 16,836,781 5,419,162 2,323,053 Michael Nohaile, Ph.D. 17,258,629 4,997,314 2,323,053 Regina Groves 16,240,666 6,015,277 2,323,053

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Fulgent Genetics, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-14 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-14

Exact text from the filing

Proposal 2 Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Votes Abstained Broker Non-Vote 24,470,414 87,192 21,390 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

Fulgent Genetics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. at the 2026-05-14 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-14

Exact text from the filing

Proposal 3 Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstained Broker Non-Vote 19,800,226 2,410,239 45,478 2,323,053

View on SEC.gov

Browse all shareholder votes →

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-224147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.